Chemokine Therapeutics Corp. Announces Final Results of CTCE-9908 Phase I/II Clinical Trial in Late Stage Cancer Patients

VANCOUVER, BRITISH COLUMBIA--(Marketwire - June 12, 2008) - Chemokine Therapeutics Corp. (the "Company") (TSX: CTI)(OTCBB: CHKT), a biotechnology company developing chemokine-based therapies to treat cancer, blood disorders, and vascular diseases, today announced positive data following the successful completion of the Phase I/II clinical trial for CTCE-9908, the Company's anti-cancer drug candidate.

Back to news